Utama › Kanser Paru-paru › Kansas › Overland Park
Kajian klinikal Kanser Paru-paru di Overland Park, KS
11 kajian untuk Kanser Paru-paru sedang mencari peserta di lokasi dalam dan sekitar Overland Park (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Mengambil pesertaFasa 3
- Saint Luke's South Hospital, Overland Park
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Mengambil pesertaFasa 1/2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Mengambil pesertaFasa 3
- University of Kansas Cancer Center-Overland Park, Overland Park
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- University of Kansas Cancer Center-Overland Park, Overland Park
Integrated Cancer Repository for Cancer Research
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Saint Luke's Cancer Instititute - South, Overland Park
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauh
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Mengambil pesertaFasa 1/2
- The University of Kansas Cancer Center, Fairway · 3 mi jauh
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Mengambil pesertaKajian pemerhatian
- Aton Health, Leawood · 3 mi jauh
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
Mengambil pesertaKajian pemerhatian
- The University of Kansas Cancer Center (KUCC), Fairway · 3 mi jauh
Kajian Kanser Paru-paru di bandar lain
- Houston, TX78 kajian
- Boston, MA62 kajian
- New York City, NY60 kajian
- Los Angeles, CA45 kajian
- Washington, DC41 kajian
- Arlington, VA41 kajian
- Chicago, IL41 kajian
- Nashville, TN40 kajian
- Baltimore, MD40 kajian
- St. Louis, MO39 kajian
- Columbus, OH37 kajian
- Philadelphia, PA36 kajian
Kajian lain di Overland Park
- Kanser Paru-paru Bukan Sel Kecil16 kajian
- Leukemia Mieloid Akut11 kajian
- Kanser Payudara10 kajian
- Kanser Kolorektal8 kajian
- Fibrilasi Atrium8 kajian
- Kanser Pankreas7 kajian
- Kanser Prostat7 kajian
- Melanoma6 kajian
- Kanser Ovari6 kajian
- Kanser Metastatik5 kajian
- Kanser Laring5 kajian
- Kanser Oral5 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.